Posts

CHINA TAKES STEPS TO ENSURE QUALITY OF COVID-19 RELATED EXPORTS

/in , /by

Chinese officials are taking steps to reduce fraudulent exports. Only products with NMPA registration can be exported to ensure standards and quality during COVID-19 crisis.

Read more

eRPS System: China National Medical Product Administration’s (NMPA) medical device registration system

/in /by

Manufacturers interested in registering a medical device in China can now submit electronic documents online through the new eRPS system.

Read more

CHINA AMENDS MEDICAL DEVICE APPLICATION SUBMISSION PROCESS

/in , /by

In an ongoing effort to refine and improve the systems and procedures for medical device registration in China, the National Medical Products Administration or NMPA (previously the CFDA) moved to a new on-line submission system and harmonized the applications table of contents to international standards.

Read more

CHINA ENCOURAGES LOCAL MANUFACTURING OF FOREIGN MEDICAL DEVICES

/in , /by

China has been making efforts to encourage more direct investment. Along with the new Foreign Investment Law, the NMPA has also announced incentives for manufacturers opening facilities in China by making the application process easier and faster. 

Read more

CHINA CHANGES CLINICAL DATA REQUIREMENTS FOR MEDICAL DEVICE REGISTRATION

/in , /by

The changes to clinical data requirements will significantly decrease the regulatory burden for many medical device manufacturers seeking to access the Chinese market by eliminating the time and expense of conducting a local clinical trial.

Read more

HONG KONG EXTENDS PILOT PROGRAM TO RECOGNIZE CHINA AND KOREA AS REFERENCE COUNTRIES

/in , /by

By allowing manufacturers to show conformity to the MDD’s assessment requirements by using NMPA or MFDS approvals, Chinese and Korean manufacturers would save 6-9 months during the application process.

Read more

CHINA WARNS MANUFACTURERS ABOUT RISK ASSESSMENT REPORT DEADLINE

/in , /by

Asia Actual works with highly experienced professionals in China that can provide you with accurate and timely Risk Assessment reports for your products that will not only satisfy the NMPA’s requirements but could also be used for updating Clinical Evaluation Reports in other markets.

Read more